RBI Discount Zert IIA 26.03.2025/ AT0000A37K55 /
13/05/2024 09:15:01 | Chg.+0.01 | Bid17:16:20 | Demandez à17:16:20 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
19.26EUR | +0.05% | - Bid taille: - |
- Ask la taille: - |
Immofinanz AG | - EUR | 26/03/2025 | Call |
GlobeNewswire
06:00
SPEE3D LAUNCHES EXPEDITIONARY MANUFACTURING UNIT (EMU) – THE COMPLETE MOBILE ADDITIVE MANUFACTURING ...
GlobeNewswire
05:01
MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible S...
GlobeNewswire
04:10
Kilmer Sports Ventures Enters into Exclusive Negotiations to Acquire French Professional Football Cl...
GlobeNewswire
03:50
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
03:00
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial Results on May 14, 2024
GlobeNewswire
03:00
GLOBAL LIFE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Bee...
GlobeNewswire
02:29
AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders...
GlobeNewswire
02:06
MBUU INVESTOR ALERT: Edelson Lechtzin LLP Urges Malibu Boats, Inc. (NASDAQ: MBUU) Shareholders With ...
GlobeNewswire
02:00
ROSEN, A LEADING LAW FIRM, Encourages Rivian Automotive, Inc. Investors With Losses in Excess of $10...
GlobeNewswire
02:00
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- an...
GlobeNewswire
02:00
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatme...
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page